SG10202112460VA - Multispecific antigen-binding molecules and uses thereof - Google Patents

Multispecific antigen-binding molecules and uses thereof

Info

Publication number: SG10202112460VA
Authority: SG; Singapore
Prior art keywords: binding molecules; multispecific antigen; multispecific; antigen; molecules
Prior art date: 2015-07-06

Nicholas Papadopoulos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-06Application filed by Regeneron PharmafiledCriticalRegeneron Pharma

2021-12-30Publication of SG10202112460VApublicationCriticalpatent/SG10202112460VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Botany (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

SG10202112460VA2015-07-062016-07-06Multispecific antigen-binding molecules and uses thereofSG10202112460VA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562188860P	2015-07-06	2015-07-06
US201662328900P	2016-04-28	2016-04-28
US201662347179P	2016-06-08	2016-06-08

Publications (1)

Publication Number	Publication Date
SG10202112460VAtrue SG10202112460VA (en)	2021-12-30

Family

ID=56464316

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10202112460VASG10202112460VA (en)	2015-07-06	2016-07-06	Multispecific antigen-binding molecules and uses thereof

Country Status (16)

Country	Link
US (3)	US11129903B2 (en)
EP (2)	EP3319994B1 (en)
JP (3)	JP6993958B2 (en)
KR (1)	KR20180025865A (en)
CN (1)	CN107849131A (en)
AU (3)	AU2016289480C1 (en)
BR (1)	BR112017027582A2 (en)
CA (1)	CA2987641A1 (en)
EA (1)	EA038973B1 (en)
ES (1)	ES2971045T3 (en)
IL (4)	IL296285A (en)
MX (2)	MX2017017117A (en)
MY (2)	MY189159A (en)
NZ (1)	NZ737726A (en)
SG (1)	SG10202112460VA (en)
WO (1)	WO2017007796A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX361875B (en)	2012-03-14	2018-12-18	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof.
CA2978942A1 (en)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
AU2016294440B2 (en)	2015-07-13	2022-10-13	Cytomx Therapeutics, Inc	Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
EP3411406B1 (en)*	2016-02-05	2025-04-09	Genmab A/S	Multispecific antigen-binding molecule with improved internalization characteristics
EP3448891A1 (en)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
HUE060983T2 (en)	2017-02-17	2023-05-28	Denali Therapeutics Inc	Engineered transferrin receptor binding polypeptides
KR20200016899A (en)	2017-06-01	2020-02-17	싸이톰스 테라퓨틱스, 인크.	Activatable anti-PDL1 antibody, and methods of using the same
US11208458B2 (en)	2017-06-07	2021-12-28	Regeneron Pharmaceuticals, Inc.	Compositions and methods for internalizing enzymes
IL308949A (en)	2017-06-22	2024-01-01	Vertex Pharma	Modified membrane-type serine protease 1 polypeptides (MTSP-1) and methods of use
IL313068A (en)	2017-11-07	2024-07-01	Regeneron Pharma	Hydrophilic linkers for antibody drug conjugates
AU2019205542A1 (en)	2018-01-08	2020-07-16	Regeneron Pharmaceuticals, Inc.	Steroids and antibody-conjugates thereof
JP2021512899A (en)	2018-02-07	2021-05-20	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Methods and Compositions for Therapeutic Protein Delivery
WO2019212965A1 (en)*	2018-04-30	2019-11-07	Regeneron Pharmaceuticals, Inc.	Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
EP3790899A1 (en)*	2018-05-09	2021-03-17	Regeneron Pharmaceuticals, Inc.	Anti-msr1 antibodies and methods of use thereof
MA52626A (en)	2018-05-17	2021-03-24	Regeneron Pharma	ANTI-CD63 ANTIBODIES, CONJUGATES AND THEIR USES
CN112638372A (en)*	2018-06-25	2021-04-09	杜克大学	Compositions and methods for treating cancers characterized by PCSK9 expression
SG11202106209RA (en)*	2018-12-19	2021-07-29	Univ Leland Stanford Junior	Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2020177717A1 (en)*	2019-03-04	2020-09-10	上海一宸医药科技有限公司	Novel bispecific binding molecule and drug conjugate thereof
CN110893236A (en)*	2019-10-09	2020-03-20	中山大学	Lysosome-targeted antibody-drug conjugates and their applications
KR20220093363A (en)*	2019-11-05	2022-07-05	리제너론 파아마슈티컬스, 인크.	N-terminal scFv multispecific binding molecule
CN111996172A (en)*	2020-09-08	2020-11-27	中国食品药品检定研究院	Method for determining biological activity of IL-4 targeted therapeutic antibody
JP2024524614A (en)	2021-07-14	2024-07-05	ライシアセラピューティクス，インコーポレイテッド	ASGPR cell surface receptor binding compounds and conjugates
JP2024545363A (en)	2021-11-16	2024-12-05	ソティオ・バイオテック・インコーポレイテッド	Treatment of Patients with Myxoid/Round Cell Liposarcoma
MX2024009563A (en)	2022-02-02	2024-08-19	Regeneron Pharma	Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease.
CN116789843B (en)*	2022-03-16	2024-09-17	伯桢生物科技(杭州)有限公司	Wnt recombinant protein and application thereof
IL317261A (en)	2022-07-29	2025-01-01	Regeneron Pharma	Non-human animals comprising a modified transferrin receptor locus
WO2025029654A2 (en)	2023-07-28	2025-02-06	Regeneron Pharmaceuticals, Inc.	Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
US20250041455A1 (en)	2023-07-28	2025-02-06	Regeneron Pharmaceuticals, Inc.	Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444878A (en)	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
US5229272A (en)	1989-04-25	1993-07-20	Igen, Inc.	Catalytic antibody components
US5156965A (en)	1983-11-29	1992-10-20	Igen, Inc.	Catalytic antibodies
US5126258A (en)	1984-09-07	1992-06-30	Scripps Clinic And Research Foundation	Molecules with antibody combining sites that exhibit catalytic properties
US5030717A (en)	1986-09-17	1991-07-09	Scripps Clinic And Research Foundation	Antibodies which catalyze hydrolysis of ester bonds
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5851527A (en)	1988-04-18	1998-12-22	Immunomedics, Inc.	Method for antibody targeting of therapeutic agents
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5858728A (en)	1991-03-13	1999-01-12	Common Services Agency	Monoclonal antibody against LPS core
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
CA2161114A1 (en)	1993-04-23	1994-11-10	Andrew D. Napper	Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
US5602021A (en)	1994-12-29	1997-02-11	Catalytic Antibodies, Inc.	Method for generating proteolytic enzymes specific against a selected peptide sequence
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6667044B1 (en)	1996-10-04	2003-12-23	Beiersdorf Ag	Cosmetic or dermatological gels based on microemulsions
ES2191827T3 (en)	1996-10-17	2003-09-16	Immunomedics Inc	CONJUGATE OF NON-ANTIGENIC TOXIN AND FUSION PROTEIN OF AN INTRACELLULAR PENETRATION RECEIVING SYSTEM.
KR20010013677A (en)	1997-06-11	2001-02-26	더 스쿨 오브 파머시, 유니버시티 오브 런던	Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
IT1293511B1 (en)	1997-07-30	1999-03-01	Gentili Ist Spa	MONOCLONAL CATALYTIC ANTIBODIES WITH PROTEASIC ACTIVITY FOR THE SELECTIVE LYSIS OF THE PROTEIN COMPONENT OF PLATES AND RELATED AGGREGATES
US6703488B1 (en)	1998-01-15	2004-03-09	Center For Molecular Medicine And Immunology	Antibody/receptor targeting moiety for enhanced delivery of armed ligand
EP1045861B1 (en)	1998-01-15	2009-03-04	Center For Molecular Medicine And Immunology	Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit
US6855804B2 (en)	1998-03-23	2005-02-15	Board Of Regents, The University Of Texas System	Covalently reactive transition state analogs and methods of use thereof
US6235714B1 (en)	1998-03-23	2001-05-22	Sudhir Paul	Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
US7138103B2 (en)	1998-06-22	2006-11-21	Immunomedics, Inc.	Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7223556B1 (en)	1998-10-09	2007-05-29	President And Fellows Of Harvard College	Targeted proteolysis by recruitment to ubiquitin protein ligases
DE60036388D1 (en)	1999-07-30	2007-10-25	Medarex Inc	THERAPEUTIC COMPOUNDS CONSISTING OF FC RECEPTOR BINDING AGENTS
AU1490801A (en)	1999-11-15	2001-05-30	University Of Southern California	Targeted delivery of therapeutic and diagnostic moieties
DE10034607A1 (en)	2000-07-20	2002-02-07	Gundram Jung	Multi-specific reagent for the selective stimulation of cell surface receptors
WO2002020740A2 (en)	2000-09-08	2002-03-14	California Institute Of Technology	Proteolysis targeting chimeric pharmaceutical
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20070258987A1 (en)	2000-11-28	2007-11-08	Seattle Genetics, Inc.	Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP2316485A1 (en)	2001-10-12	2011-05-04	Schering Corporation	Use of bispecific antibodies to regulate immune responses
ES2349235T3 (en)	2001-12-21	2010-12-29	Alcon, Inc.	USE OF SYNTHETIC INORGANIC NANOPARTICLES AS VEHICLES FOR OPHTHALMIC DRUGS.
US7332585B2 (en)	2002-04-05	2008-02-19	The Regents Of The California University	Bispecific single chain Fv antibody molecules and methods of use thereof
AU2004249903B2 (en)	2003-06-18	2009-06-04	Bayer Schering Pharma Aktiengesellschaft	New biological entities and the use thereof
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
CN1886426A (en)	2003-11-07	2006-12-27	伊姆尼斯公司	Antibodies that bind interleukin-4 receptor
US7371539B2 (en)	2003-12-03	2008-05-13	President And Fellows Of Harvard College	Targeted polypeptide degradation
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
EP1718667B1 (en)	2004-02-23	2013-01-09	Genentech, Inc.	Heterocyclic self-immolative linkers and conjugates
US8754031B2 (en)*	2004-03-08	2014-06-17	Oncolix, Inc.	Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
AR048098A1 (en)	2004-03-15	2006-03-29	Wyeth Corp	CALIQUEAMYCIN CONJUGATES
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
CA2633486C (en)*	2005-12-16	2015-02-03	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
US7750116B1 (en)	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
MY147468A (en)	2006-06-02	2012-12-14	Regeneron Pharma	High affinity antibodies to human il-6 receptor
US9127293B2 (en)*	2006-07-26	2015-09-08	The University Of Chicago	Receptor-mediated delivery: compositions and methods
WO2008019290A2 (en)	2006-08-04	2008-02-14	Astrazeneca Ab	Human antibodies to erbb 2
EA201201533A1 (en)*	2006-08-18	2014-11-28	Новартис Аг	PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
WO2008122039A2 (en)	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (en)	2007-05-23	2019-06-24	Ventana Med Syst Inc	Polymer carriers for immunohistochemistry and in situ hybridization
US20090258005A1 (en)	2007-05-29	2009-10-15	Trubion Pharmaceuticals Inc.	Therapeutic compositions and methods
WO2008151219A1 (en)	2007-06-04	2008-12-11	Regeneron Pharmaceuticals, Inc.	Enhanced expression and stability regions
WO2009018386A1 (en)	2007-07-31	2009-02-05	Medimmune, Llc	Multispecific epitope binding proteins and uses thereof
WO2009094561A1 (en)	2008-01-24	2009-07-30	The Government Of The United States Of America As Represented By The Secretary Of The Departmentof	Induced internalization of surface receptors
PL2274008T3 (en)	2008-03-27	2014-07-31	Zymogenetics Inc	Compositions and methods for inhibiting pdgfrbeta and vegf-a
KR20100137585A (en)	2008-04-30	2010-12-30	이뮤노젠 아이엔씨	Strong Complexes and Hydrophilic Linkers
PL2326349T3 (en)	2008-07-21	2015-08-31	Polytherics Ltd	Novel reagents and method for conjugating biological molecules
CN102643345A (en)	2008-09-26	2012-08-22	罗氏格黎卡特股份公司	Bispecific anti-egfr/anti-igf-1r antibodies
JP5587975B2 (en)	2009-04-07	2014-09-10	ロシュグリクアートアクチェンゲゼルシャフト	Bispecific anti-ErbB-3 / anti-c-Met antibody
EP2241576A1 (en)	2009-04-17	2010-10-20	Trion Pharma Gmbh	Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
KR20120027055A (en)	2009-06-26	2012-03-20	리제네론 파라마큐티칼스 인코포레이티드	Readily isolated bispecific antibodies with native immunoglobulin format
CA2770626A1 (en)	2009-08-10	2011-02-17	Mark Smith	Functionalisation of solid substrates
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2332995A1 (en)	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralizing prolactin receptor antibodies and their therapeutic use
AU2011213585B2 (en)	2010-02-08	2014-02-06	Regeneron Pharmaceuticals, Inc.	Common light chain mouse
EP2528625B1 (en)	2010-04-15	2013-07-10	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
CN114805583A (en)	2010-05-27	2022-07-29	根马布股份公司	Monoclonal antibody against HER2
WO2012005982A2 (en)	2010-07-06	2012-01-12	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Reporter for rna polymerase ii termination
WO2012136519A1 (en)	2011-04-06	2012-10-11	Bayer Pharma Aktiengesellschaft	Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
CN103502273A (en)	2011-04-20	2014-01-08	罗氏格黎卡特股份公司	Method and constructs for the pH dependent passage of the blood-brain-barrier
JP2014514314A (en)	2011-04-20	2014-06-19	ゲンマブエー／エス	Bispecific antibodies against HER2 and CD3
CN103796678B (en)	2011-04-20	2018-02-27	健玛保	For HER2 bispecific antibody
CN103702996A (en)	2011-05-27	2014-04-02	Ambrx公司	Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
EP2530089A1 (en)	2011-06-03	2012-12-05	Bayer Pharma Aktiengesellschaft	Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8815226B2 (en)	2011-06-10	2014-08-26	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
JP6170497B2 (en)	2011-10-14	2017-07-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	Pyrrolobenzodiazepine
EP2751076B1 (en)	2011-10-14	2018-04-25	MedImmune Limited	Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
CN103987384A (en)	2011-10-14	2014-08-13	西雅图基因公司	Pyrrolobenzodiazepines and targeted conjugates
KR101961976B1 (en)	2011-10-14	2019-03-25	시애틀 지네틱스, 인크.	Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en)	2011-11-11	2013-05-16	Pfizer Inc.	Antibody-drug conjugates
US20130224228A1 (en)	2011-12-05	2013-08-29	Igenica, Inc.	Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
MX361875B (en)	2012-03-14	2018-12-18	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof.
AU2013258844B2 (en)	2012-05-10	2017-12-21	Zymeworks Bc Inc.	Single-arm monovalent antibody constructs and uses thereof
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
FI3912642T3 (en)	2012-10-23	2023-07-07	Synaffix Bv	Modified antibody, antibody-conjugate and process for the preparation thereof
TWI635098B (en)	2013-02-01	2018-09-11	再生元醫藥公司	Antibodies comprising chimeric constant domains
US9023357B2 (en)	2013-03-15	2015-05-05	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
AU2014233385C1 (en)	2013-03-15	2019-09-19	Regeneron Pharmaceuticals, Inc.	Biologically active molecules, conjugates thereof, and therapeutic uses
AU2014262566A1 (en)	2013-05-08	2015-11-12	Zymeworks Inc.	Bispecific HER2 and HER3 antigen binding constructs
US9388243B2 (en)	2013-05-29	2016-07-12	Samsung Electronics Co., Ltd.	Method of target membrane protein depletion
TWI641620B (en)	2013-08-21	2018-11-21	再生元醫藥公司	Anti-prlr antibodies and uses thereof
US9545451B2 (en)	2013-08-21	2017-01-17	Regeneron Pharmaceuticals, Inc.	Anti-PRLR antibodies and methods for killing PRLR-expressing cells
BR112016004023A2 (en)	2013-08-26	2022-11-16	Regeneron Pharma	COMPOSITION, METHODS FOR PREPARING A COMPOSITION AND FOR TREATMENT OF A DISEASE, AND COMPOUND
BR112017020149A8 (en)	2015-03-27	2023-05-02	Regeneron Pharma	MAITANSINOID DERIVATIVES, CONJUGATES THEREOF AND METHODS OF USE
CN108779127B (en)	2016-01-25	2022-07-05	里珍纳龙药品有限公司	Maytansinoid derivatives, conjugates thereof, and methods of use
EP3411406B1 (en)	2016-02-05	2025-04-09	Genmab A/S	Multispecific antigen-binding molecule with improved internalization characteristics

2016
- 2016-07-06KRKR1020177036740Apatent/KR20180025865A/enactivePending
- 2016-07-06USUS15/202,822patent/US11129903B2/enactiveActive
- 2016-07-06CNCN201680037806.5Apatent/CN107849131A/enactivePending
- 2016-07-06ILIL296285Apatent/IL296285A/enunknown
- 2016-07-06WOPCT/US2016/041055patent/WO2017007796A1/enactiveApplication Filing
- 2016-07-06SGSG10202112460VApatent/SG10202112460VA/enunknown
- 2016-07-06EPEP16741208.9Apatent/EP3319994B1/enactiveActive
- 2016-07-06EPEP20173448.0Apatent/EP3722318A1/enactivePending
- 2016-07-06MXMX2017017117Apatent/MX2017017117A/enunknown
- 2016-07-06JPJP2018500528Apatent/JP6993958B2/enactiveActive
- 2016-07-06ESES16741208Tpatent/ES2971045T3/enactiveActive
- 2016-07-06MYMYPI2017704363Apatent/MY189159A/enunknown
- 2016-07-06EAEA201890222Apatent/EA038973B1/enunknown
- 2016-07-06CACA2987641Apatent/CA2987641A1/enactivePending
- 2016-07-06USUS15/738,801patent/US11191844B2/enactiveActive
- 2016-07-06MYMYPI2020006735Apatent/MY197218A/enunknown
- 2016-07-06AUAU2016289480Apatent/AU2016289480C1/enactiveActive
- 2016-07-06ILIL313163Apatent/IL313163B1/enunknown
- 2016-07-06BRBR112017027582Apatent/BR112017027582A2/enactiveSearch and Examination
- 2016-07-06NZNZ737726Apatent/NZ737726A/enunknown
2017
- 2017-12-19ILIL256416Apatent/IL256416B/enunknown
- 2017-12-20MXMX2023003418Apatent/MX2023003418A/enunknown
2020
- 2020-11-02JPJP2020183501Apatent/JP7285813B2/enactiveActive
2021
- 2021-08-20AUAU2021218213Apatent/AU2021218213C1/enactiveActive
- 2021-09-23USUS17/483,588patent/US20220008548A1/enactivePending
- 2021-11-04ILIL287848Apatent/IL287848A/enunknown
2023
- 2023-03-07JPJP2023034161Apatent/JP2023071899A/enactivePending
2024
- 2024-12-13AUAU2024278415Apatent/AU2024278415A1/enactivePending

Also Published As

Publication number	Publication date
AU2021218213A1 (en)	2021-09-09
US20220008548A1 (en)	2022-01-13
EP3722318A1 (en)	2020-10-14
JP2023071899A (en)	2023-05-23
EA038973B1 (en)	2021-11-17
MY197218A (en)	2023-06-02
EA201890222A1 (en)	2018-06-29
JP6993958B2 (en)	2022-02-04
US20190000984A1 (en)	2019-01-03
US11129903B2 (en)	2021-09-28
IL287848A (en)	2022-01-01
NZ777967A (en)	2024-10-25
ES2971045T3 (en)	2024-06-03
AU2016289480A1 (en)	2017-12-07
AU2024278415A1 (en)	2025-01-09
BR112017027582A2 (en)	2018-08-28
CN107849131A (en)	2018-03-27
US11191844B2 (en)	2021-12-07
NZ777968A (en)	2024-10-25
AU2016289480B2 (en)	2021-05-20
AU2016289480C1 (en)	2021-10-21
IL296285A (en)	2022-11-01
EP3319994B1 (en)	2024-02-07
WO2017007796A4 (en)	2017-03-23
KR20180025865A (en)	2018-03-09
MX2023003418A (en)	2023-04-14
IL313163B1 (en)	2025-02-01
AU2021218213C1 (en)	2025-01-02
EP3319994A1 (en)	2018-05-16
IL256416A (en)	2018-04-30
IL313163A (en)	2024-07-01
AU2021218213B2 (en)	2024-09-19
JP7285813B2 (en)	2023-06-02
MX2017017117A (en)	2018-03-06
CA2987641A1 (en)	2017-01-12
JP2018524358A (en)	2018-08-30
MY189159A (en)	2022-01-29
JP2021020963A (en)	2021-02-18
NZ737726A (en)	2023-03-31
EP3319994C0 (en)	2024-02-07
WO2017007796A1 (en)	2017-01-12
IL256416B (en)	2021-12-01
US20170007715A1 (en)	2017-01-12
NZ777971A (en)	2024-10-25

Publication	Publication Date	Title
IL287848A (en)	2022-01-01	Multispecific antigen-binding molecules and uses thereof
IL285366A (en)	2021-09-30	Multispecific antigen-binding proteins
IL290571A (en)	2022-04-01	Pd-1-binding molecules and methods of use thereof
HK1257760A1 (en)	2019-10-25	Multispecific antibodies
HK1252827A1 (en)	2019-06-06	Lag-3-binding molecules and methods of use thereof
IL254223A (en)	2017-10-31	Cd20 binding molecules and uses thereof
GB201521858D0 (en)	2016-01-27	Small molecules
GB201615617D0 (en)	2016-10-26	Small molecules
HK1252791A1 (en)	2019-06-06	Binding molecules with modified j-chain
GB201412659D0 (en)	2014-08-27	Molecules
IL277261A (en)	2020-10-29	Small molecules against cancer
GB201412658D0 (en)	2014-08-27	Molecules
HK1248721A1 (en)	2018-10-19	Antibody molecules and uses thereof
GB201522391D0 (en)	2016-02-03	Antibody molecules
GB201501593D0 (en)	2015-03-18	New compounds and processes
IL252932A0 (en)	2017-08-31	Anti-cxcl12 antibody molecules and their uses
GB201516922D0 (en)	2015-11-11	New processes and compounds

Movatterモバイル変換

SG10202112460VA - Multispecific antigen-binding molecules and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=56464316

Family Applications (1)

Country Status (16)

Families Citing this family (28)

Family Cites Families (99)

Also Published As

Similar Documents